Scattering mechanisms and spectral properties of the one-dimensional Hubbard model

It is found that the finite-energy spectral properties of the one-dimensional Hubbard model are controlled by the scattering of charged $\eta$-spin-zero $2\nu$-holon composite objects, spin-zero $2\nu$-spinon composite objects, and charged $\eta$-spin-less and spin-less objects, rather than by the scattering of independent $\eta$-spin 1/2 holons and spin 1/2 spinons. Here $\nu =1,2,...$. The corresponding $S$ matrix is calculated and its relation to the spectral properties is clarified.Comment: 8 pages, no figure

Phase diagram and magnetic collective excitations of the Hubbard model in graphene sheets and layers

We discuss the magnetic phases of the Hubbard model for the honeycomb lattice both in two and three spatial dimensions. A ground state phase diagram is obtained depending on the interaction strength U and electronic density n. We find a first order phase transition between ferromagnetic regions where the spin is maximally polarized (Nagaoka ferromagnetism) and regions with smaller magnetization (weak ferromagnetism). When taking into account the possibility of spiral states, we find that the lowest critical U is obtained for an ordering momentum different from zero. The evolution of the ordering momentum with doping is discussed. The magnetic excitations (spin waves) in the antiferromagnetic insulating phase are calculated from the random-phase-approximation for the spin susceptibility. We also compute the spin fluctuation correction to the mean field magnetization by virtual emission/absorpion of spin waves. In the large $U$ limit, the renormalized magnetization agrees qualitatively with the Holstein-Primakoff theory of the Heisenberg antiferromagnet, although the latter approach produces a larger renormalization

The TTF finite-energy spectral features in photoemission of TTF-TCNQ: The Hubbard-chain description

A dynamical theory which accounts for all microscopic one-electron processes is used to study the spectral function of the 1D Hubbard model for the whole $(k, \omega)$-plane, beyond previous studies which focused on the weight distribution in the vicinity of the singular branch lines only. While our predictions agree with those of the latter studies concerning the tetracyanoquinodimethane (TCNQ) related singular features in photoemission of the organic compound tetrathiafulvalene-tetracyanoquinodimethane (TTF-TCNQ) metallic phase, the generalized theory also leads to quantitative agreement concerning the tetrathiafulvalene (TTF) related finite-energy spectral features, which are found to correspond to a value of the on-site repulsion $U$ larger than for TCNQ. Our study reveals the microscopic mechanisms behind the unusual spectral features of TTF-TCNQ and provides a good overall description of those features for the whole $(k, \omega)$-plane.Comment: To appear in Journal of Physics: Condensed Matte

Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort

Background: As gene-targeted therapies are increasingly being developed for Parkinson's disease (PD), identifying and characterizing carriers of specific genetic pathogenic variants is imperative. Only a small fraction of the estimated number of subjects with monogenic PD worldwide are currently represented in the literature and availability of clinical data and clinical trial-ready cohorts is limited. Objective: The objectives are to (1) establish an international cohort of affected and unaffected individuals with PD-linked variants; (2) provide harmonized and quality-controlled clinical characterization data for each included individual; and (3) further promote collaboration of researchers in the field of monogenic PD. Methods: We conducted a worldwide, systematic online survey to collect individual-level data on individuals with PD-linked variants in SNCA, LRRK2, VPS35, PRKN, PINK1, DJ-1, as well as selected pathogenic and risk variants in GBA and corresponding demographic, clinical, and genetic data. All registered cases underwent thorough quality checks, and pathogenicity scoring of the variants and genotype–phenotype relationships were analyzed. Results: We collected 3888 variant carriers for our analyses, reported by 92 centers (42 countries) worldwide. Of the included individuals, 3185 had a diagnosis of PD (ie, 1306 LRRK2, 115 SNCA, 23 VPS35, 429 PRKN, 75 PINK1, 13 DJ-1, and 1224 GBA) and 703 were unaffected (ie, 328 LRRK2, 32 SNCA, 3 VPS35, 1 PRKN, 1 PINK1, and 338 GBA). In total, we identified 269 different pathogenic variants; 1322 individuals in our cohort (34%) were indicated as not previously published. Conclusions: Within the MJFF Global Genetic PD Study Group, we (1) established the largest international cohort of affected and unaffected individuals carrying PD-linked variants; (2) provide harmonized and quality-controlled clinical and genetic data for each included individual; (3) promote collaboration in the field of genetic PD with a view toward clinical and genetic stratification of patients for gene-targeted clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): study protocol for a randomized controlled trial

BACKGROUND: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). METHODS/DESIGN: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH2O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure 6430 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. DISCUSSION: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration metho

Using global team science to identify genetic parkinson's disease worldwide.

No abstract available